CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Andelyn Biosciences to develop GM2 gangliosidosis therapy

PartnershipAAV9-GM2Positive
AI Analysis

Summary

Andelyn Biosciences has entered into an agreement with Queen's University to develop and manufacture AAV9-GM2, a gene therapy for treating GM2 gangliosidosis including Tay-Sachs and Sandhoff diseases.

Importance:5/10
Sentiment:
0.50
gene therapyAAV9rare diseasepartnershipTay-SachsSandhoff disease

Read the original article

Published by Pharmaceutical Technology on August 19, 2026 9:04 AM

Read Original